Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03365102 · ClinicalTrials.gov registry record · NA
Modulating Impulsivity in Suicidal Adolescents With Transcranial Direct Current Stimulation (tDCS)
A NA study, sponsored by Lifespan.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT03365102 is a NA study that has completed, run by Lifespan. The registered enrollment target is 64 participants.
The verdict
NCT03365102, a NA study, has completed, sponsored by Lifespan.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
As a first step toward investigating whether modulation of impulsivity and associated neural pathways may yield clinically meaningful changes in risk for adolescent suicidal behavior, the R21 is a proof-of concept study evaluating the potential for tDCS targeting brain regions associated with behavioral impulsivity (right inferior frontal gyrus \[rIFG\]) and cognitive impulsivity (left orbitofrontal cortex \[lOFC\]) to modulate these facets of impulsivity in a sample of adolescent suicide attempters. Participants will be randomly assigned to receive anodal tDCS over the rIFG, anodal tDCS over the lOFC, or a sham stimulation condition, in a three-group design. Task-based measures of behavioral and cognitive impulsivity will be administered before and after tDCS or sham stimulation. Additionally, electroencephalography (EEG) and event-related potential (ERP) data will be collected during the impulsivity tasks, and resting-state EEG data will be collected pre- and post-tDCS administration to confirm engagement of the targeted brain regions and to delineating the neural pathways underlying the effects of tDCS on impulsivity.
Interventions
- DEVICE anodal tDCS over the rIFG,
- DEVICE anodal tDCS over the lOFC,
- DEVICE sham tDCS stimulation condition
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03365102
The ClinicalTrials.gov registry entry for NCT03365102 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lifespan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which anodal tDCS over the rIFG, is the first listed.
NCT03365102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03365102 about?
NCT03365102 is a clinical study titled "Modulating Impulsivity in Suicidal Adolescents With Transcranial Direct Current Stimulation (tDCS)". As a first step toward investigating whether modulation of impulsivity and associated neural pathways may yield clinically meaningful changes in risk for adolescent suicidal behavior, the R21 is a proof-of concept study evaluating the potential for tDCS targeting brain regions associated with behavi...
What is the current status of trial NCT03365102?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2017-04-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03365102?
The interventions under investigation include: anodal tDCS over the rIFG, (DEVICE), anodal tDCS over the lOFC, (DEVICE), sham tDCS stimulation condition (DEVICE).
Who is sponsoring clinical trial NCT03365102?
This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.